Recent Company News

• 01:03 AM ET Oct 08, 2026
  

  Newron Pharmaceuticals receives the anticipated FDA written communication on clinical hold at U.S. study centers in its Phase 3 ENIGMA-TRS 2 study with evenamide (CHF 7.45, 0.00)

• 10:59 AM ET Oct 06, 2026
  

  StreetAccount Sector Summary - China Healthcare September Recap

• 11:48 AM ET Sep 25, 2026
  

  FDA announces hold on enrollment of new patients will remain in place at US sites in Phase 3 ENIGMA-TRS 2 study with evenamide (CHF 10.46, 0.00)

• 04:47 PM ET Sep 24, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 03:21 PM ET Sep 24, 2026
  

  FDA approves Welireg + Lenvima combo for adults with 2L+ ccRCC ($148.85, +0.77)

• 08:45 AM ET Sep 24, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 10:20 AM ET Sep 22, 2026
  

  BioArctic AB notes first patient treated with Leqembi (lecanemab) in Sweden (SEK 325.40, +5.00)

• 06:36 AM ET Sep 18, 2026
  

  EU's CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for Jyseleca

• 07:35 AM ET Sep 17, 2026
  

  Nuvation Bio issues PR for FDA approval of sNDA for IBTROZI in ROS1-Positive NSCLC ($5.78, 0.00)

• 02:10 AM ET Sep 16, 2026
  

  Eisai, Biogen's LEQEMBI Pen obtains Japan approval as new route of administration for treatment for early Alzheimer's Disease (¥4771.0000, +4)